BD - Earth day 2024

Kansas City Proton Institute Embarks on Cancer Treatment Journey with Cutting-edge MEVION S250i Proton Therapy System

Saturday, December 23, 2023

Kansas City Proton Institute (KCPI), the leading physician-directed proton therapy center in the Midwest, marked a significant achievement with the treatment of the first four patients using the state-of-the-art MEVION S250i Proton Therapy System®. The institute, now housed in a newly inaugurated 34,000-square-foot facility in Overland Park, Kansas, proudly hosts the region's first Mevion compact proton therapy system.

Situated at 5300 Indian Creek Parkway, the facility's design prioritizes patient convenience, featuring a two-story structure with a partial basement and ample parking. An official open house and ribbon-cutting ceremony are scheduled for early 2024 to celebrate the unveiling of this cutting-edge facility.

At the core of KCPI's offerings lies Mevion’s HYPERSCAN® pencil beam scanning technology for Intensity Modulated Proton Therapy (IMPT) with a proton MLC. This innovative combination allows for the precise delivery of radiation doses to tumors while safeguarding the surrounding healthy tissues and organs. Particularly beneficial for treating tumors in sensitive areas such as the head and neck, spinal cord, breasts, esophagus, prostate, lung, bone, stomach, colon, and bladder.

The MEVION S250i system at KCPI is equipped with an advanced 3D imaging system and will soon integrate the C-RAD Catalyst PT surface-guided tracking system. This integration ensures a cutting-edge Image-Guided Proton Therapy configuration, optimizing patient positioning and intra-fraction motion management.

Proton therapy, known for its precision, minimizes unnecessary radiation exposure to healthy tissue, potentially reducing side effects and lowering the risk of secondary malignancies. The innovative features of HYPERSCAN technology, including optimal spot sizes and hyper-fast layer switching, contribute to faster and more precise dose delivery. Coupled with a multi-layer proton MLC, this capability allows clinicians at KCPI to administer a full field of therapeutic radiation in a single breath-hold, minimizing sensitivity to motion.

Affiliated with Kansas City Urology & Oncology (KCUC), KCPI benefits from the extensive experience of its physicians in treating various cancer types, including those affecting the prostate, head/neck, breast, lung, brain, gastrointestinal system, liver, and skin. Those seeking additional information about Kansas City Urology & Oncology are encouraged to explore details directly from the institute.





Healthcare CEO & Executive Strategy SummitHealthcare CNO SummitHealthcare CMO SummitHealthcare CFO, Financial Strategy & Revenue Cycle SummitThe Healthcare Patient Experience & Engagement Summit 2024Healthcare Innovation & Transformation Summit